Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 29Gynecologic 6Gastrointestinal 4Thoracic 3Genitourinary 3Sarcoma 2Classical hematology 1

Conditions

Small Cell Lung Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Neoplasms 1Fanconi Anemia, Complementation Group D1 1

Interventions

pembrolizumab 38Docetaxel 23Paclitaxel 20Trastuzumab 19Cyclophosphamide 18Gemcitabine 17Carboplatin 17Magnetic Resonance Spectroscopy 16Radiotherapy 14Nivolumab 13Radiosurgery 12Surveys and Questionnaires 11Specimen Handling 10Fulvestrant 10fludarabine 9aldesleukin 9Vinorelbine 9Blood Specimen Collection 9Taxes 8Injections 8Drug Therapy 8Cisplatin 8Capecitabine 8Bevacizumab 8Standard of Care 7Psychiatric Rehabilitation 7Fluorodeoxyglucose F18 7Early Intervention, Educational 7sargramostim 6palbociclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × talazoparib × Thoracic × Clear all
NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Pfizer

Phase 1/2 Terminated
223 enrolled 50 charts
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

Phase 1 Completed
113 enrolled 39 charts
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡